SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved ...
In the Archway study, Port Delivery System with ranibizumab (PDS) demonstrated non-inferior and equivalent visual acuity outcomes compared with monthly ranibizumab eye injections, and a favorable ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the Phase III Archway study, evaluating ...
<0> GenentechMedia Contact:Terence Hurley, 650-467-6800orInvestor Relations:Thomas Kudsk Larsen, 650-467-2016Karl Mahler, 011 41 61 687 8503 </0> Genentech, a member of the Roche Group (SIX: RO, ROG; ...
More recently established treatments for RVO have taken a giant leap forward from laser photocoagulation since intravitreally ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the ...
A recent study found that the ranibizumab port delivery system (PDS) has cost-saving potential compared with regular ranibizumab or aflibercept injections for age-related macular degeneration if used ...
Ranibizumab implants approved by FDA for DME offer a more convenient treatment schedule, reducing injection frequency significantly. The phase 3 Pagoda study showed noninferior visual acuity with ...
Please provide your email address to receive an email when new articles are posted on . VANCOUVER, British Columbia — While eye pain outcomes were similar within a week of injection of either ...
Please provide your email address to receive an email when new articles are posted on . Data from the ZIPANGU study showed the use of focal/grid short-pulse laser therapy in patients receiving ...
Ranibizumab, an anti-vascular endothelial growth factor, and dexamethasone, a corticosteroid, have been shown to be effective in treating macular oedema secondary to retinal vein occlusion (RVO) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results